Assignee
CYMABAY THERAPEUTICS INC
US·35 granted patents·19 pending applications·140 citations·filing 2012–2025
Top patents by PatentIndex Score
54 records- 0196US9616039B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2016·Granted Apr 11, 2017·31 cites·12 claims
- 0296US9381181B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2015·Granted Jul 5, 2016·38 cites·6 claims
- 0394US9486428B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2015·Granted Nov 8, 2016·14 cites·6 claims
- 0492US10512622B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·4 cites·10 claims
- 0591US10188620B2Treatment for NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·7 cites·19 claims
- 0691US9962346B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2017·Granted May 8, 2018·8 cites·13 claims
- 0790US9808436B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2016·Granted Nov 7, 2017·6 cites·9 claims
- 0890US9060987B2Methods for treating gout flaresCYMABAY THERAPEUTICS INC·Filed 2012·Granted Jun 23, 2015·5 cites·16 claims
- 0989US10272058B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2017·Granted Apr 30, 2019·5 cites·16 claims
- 1088US9439891B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Sep 13, 2016·3 cites·16 claims
- 1188US9433612B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Sep 6, 2016·3 cites·23 claims
- 1287US10813895B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Oct 27, 2020·1 cites·16 claims
- 1386US10828273B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·1 cites·9 claims
- 1486US10722483B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2019·Granted Jul 28, 2020·1 cites·19 claims
- 1586US10342770B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2018·Granted Jul 9, 2019·3 cites·19 claims
- 1685US10813896B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Oct 27, 2020·1 cites·10 claims
- 1785US8993797B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2013·Granted Mar 31, 2015·2 cites·8 claims
- 1882US10220011B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·2 cites·9 claims
- 1979US10478411B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Nov 19, 2019·1 cites·16 claims
- 2078US9801860B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Oct 31, 2017·1 cites·20 claims
- 2178US9737537B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·1 cites·2 claims
- 2277US11596614B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2021·Granted Mar 7, 2023·0 cites·16 claims
- 2375US11000494B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted May 11, 2021·0 cites·16 claims
- 2475US9233914B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2015·Granted Jan 12, 2016·1 cites·6 claims
- 2574US11406611B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted Aug 9, 2022·0 cites·9 claims
- 2673US11179359B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2020·Granted Nov 23, 2021·0 cites·19 claims
- 2772US11224580B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted Jan 18, 2022·0 cites·12 claims
- 2871US10292983B2Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditionsCYMABAY THERAPEUTICS INC·Filed 2017·Granted May 21, 2019·1 cites·22 claims
- 2969US11007162B2Methods of reducing small, dense LDL particlesCYMABAY THERAPEUTICS INC·Filed 2018·Granted May 18, 2021·0 cites·10 claims
- 3069US10137112B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2017·Granted Nov 27, 2018·0 cites·9 claims
- 3169US2026055055A1Process for making seladelparCYMABAY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3267US9925189B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2017·Granted Mar 27, 2018·0 cites·2 claims
- 3364US9845285B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2015·Granted Dec 19, 2017·0 cites·20 claims
- 3464US8921350B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2013·Granted Dec 30, 2014·0 cites·4 claims
- 3563US2024252499A1Treatment of uremic pruritusCYMABAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3663US2024252500A1Treatment of chronic pruritic dermatosesCYMABAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3762US2021283078A1Treatment of cholestatic pruritusCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3861US9150567B2Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine saltsCYMABAY THERAPEUTICS INC·Filed 2014·Granted Oct 6, 2015·0 cites·5 claims
- 3960US2019105291A1Treatment of cholestatic pruritusCYMABAY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4059US2018055803A1Methods for Treating Gout FlaresCYMABAY THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4159US2026060948A1Methods for treating liver diseaseCYMABAY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4258US2022241228A1Treatment of cholangiopathiesCYMABAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4356US2021355065A1CB-0406 tromethamine saltCYMABAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4456US2021355066A1CB-0406 choline saltCYMABAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4553US2020155650A1Combination treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4653US2020155487A1Treatment of obesity and its complicationsCYMABAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4750US10098843B2Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidineCYMABAY THERAPEUTICS INC·Filed 2016·Granted Oct 16, 2018·0 cites·15 claims
- 4849US2021145775A1Treatment of intestinal barrier dysfunction and associated diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4949US2021145774A1Treatment of alcoholic liver diseaseCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5047US2016324811A1Methods of reducing small, dense ldl particlesCYMABAY THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CYMABAY THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →